Selective GABA A Receptor Modulator for Neuropathic Pain
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for neuropathic pain and itch associated with GABA A receptor modulation are limited by undesirable side effects and lack of disease modification, with many modulators affecting the α1 subunit leading to adverse effects such as sedation and cognitive impairment, while existing treatments for itch are often ineffective.
Innovation Solution
The compound 2-(3-(3-(2,4-dimethoxypyrimidin-5-yl)phenyl)-3H-imidazo[4,5-b]pyridin-6-yl)propan-2-ol acts as a novel positive allosteric modulator preferentially targeting the α3 subunit of GABA A receptors, offering analgesic and antipruritic effects without significant activation of α1 subunits, thus minimizing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If classical benzodiazepines are used to modulate GABA A receptors, then analgesic effects are achieved, but sedation, dependency, and cognitive impairment occur due to activation of α1 subunits
Solution Approach 1:
The patent applies local quality by designing a compound that selectively targets specific subunit compositions (α2α5βγ2 and/or α3βγ2) rather than all GABA A receptors uniformly. This selective modulation achieves analgesia while avoiding activation of α1-containing receptors that cause sedation and cognitive impairment, thus resolving the contradiction between therapeutic effect and side effects.
Solution Approach 2:
The patent changes the selectivity parameter of the GABA A receptor modulator to preferentially bind to receptors containing α2, α3, and/or α5 subunits with higher affinity than α1 subunits. This parameter change in subunit selectivity allows the compound to maintain analgesic efficacy while eliminating the harmful side effects associated with α1 activation.
2Ease of operation
If current therapies are used for neuropathic pain management, then symptomatic relief is provided, but disease modification is not achieved and tolerance develops
Solution Approach 1:
The patent introduces a dynamic approach by using a selective GABA A receptor modulator that can adaptively enhance inhibitory neurotransmission in pain pathways without inducing tolerance. The compound maintains its efficacy over chronic dosing periods by selectively modulating receptor subtypes involved in pain transmission, enabling both symptomatic relief and potential disease modification without the tolerance development seen with conventional therapies.
3Adaptability or versatility
If GABA A receptor modulators are used to treat itch, then potential therapeutic activity is achieved, but existing treatments are often ineffective or lack disease modification
Solution Approach 1:
The patent applies local quality by targeting specific GABA A receptor subunit compositions that are implicated in itch pathways. The selective modulation of α2α5βγ2 and/or α3βγ2 containing receptors provides effective itch relief while avoiding off-target effects, thereby improving treatment effectiveness and reliability for pruritus management.
Data Source
Figure 1A~1B
Figure 2
Figure 3
AI summary
The present invention relates to 2-(3-(3-(2,4-dimethoxypyrimidin-5-yl)phenyl)-3H- imidazo[4,5-b]pyridin-6-yl)propan-2-ol, which is useful as a GABA receptor modulator. In one embodiment, said compound is useful in the treatment of pain, neuropathic pain and/or itch.